EG-1962: Clinical Trials

3 trials of EG-1962, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 2 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Terminated 1
Phase 21Completed 1
Phase 31Terminated 1

Follow EG-1962: new trials by email Literature Review of EG-1962 trials Research Report on EG-1962

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH
EG-1962 (nimodipine microparticles), Enteral Nimodipine - Subarachnoid Hemorrhage, Aneurysmal
Phase 1TerminatedEdge Therapeutics Inc62016-09-012018-07-26
Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
EG-1962 (nimodipine microparticles), Enteral Nimodipine - Subarachnoid Hemorrhage, Aneurysmal
Phase 3TerminatedEdge Therapeutics Inc3742016-07-012018-07-26
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine, Nimodipine Microparticles - Ruptured Cerebral Aneurysm, Ruptured Berry Aneurysm
Phase 1 / Phase 2CompletedEdge Therapeutics Inc732013-09-012018-02-05

Conditions studied

Subarachnoid Hemorrhage (3)  ·  Aneurysm (1)  ·  Aneurysm, Ruptured (1)  ·  Rupture (1)

Sponsors

Edge Therapeutics Inc (3)

Countries

Canada (3)  ·  United States (3)  ·  Czechia (2)  ·  Finland (2)  ·  Australia (1)  ·  Austria (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Israel (1)  ·  New Zealand (1)  ·  Singapore (1)

Top investigators

R. Loch Macdonald, MD, PhD (2)  ·  Daniel Hanggi (1)

Results publications

PMID 25678453, PMID 27932607, PMID 30014184, PMID 31812149, PMID 32138631, PMID 32985652, PMID 37624739